To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH

Conditions:   Langerhans Cell Histiocytosis;   LCH Intervention:   Drug: FCN-159 Sponsor:   Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials